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ABSTRACT The 2018 European Respiratory Society (ERS) International Congress held in Paris, France,
served as a platform to discover the latest research on respiratory diseases, the improvement in their
treatments and patient care. Specifically, the scientific sessions organised by ERS Assembly 4 provided
novel insights into sleep disordered breathing and fresh knowledge in respiratory physiology, stressing its
importance to understanding and treating respiratory diseases. This article, divided by session, will
summarise the most relevant studies presented at the ERS International Congress. Each session has been
written by early career members specialised in the different fields of this interdisciplinary assembly.
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CONGRESS HIGHLIGHTS
SLEEP AND CLINICAL PHYSIOLOGY
Pathophysiological aspects of sleep disordered breathing: intermittent hypoxia
Obstructive sleep apnoea (OSA) has been associated with a wide variety of cardiovascular, neurocognitive
and metabolic consequences. Intermittent hypoxia (IH), a hallmark of OSA, has been suggested to play an
important role in the development of cardiovascular disease. Proposed mechanisms include sympathetic
activation, oxidative stress and systemic inflammation.
MOULIN et al. [1] explored the role of hypoxia inducible factor-1 (HIF-1) signalling in IH-induced
cardiovascular injury. They took HIF-1+/− and wild-type mice, and exposed them to 21 days of either IH
or normoxia. The marked effects of IH on mitochondrial respiration, reactive oxygen species production
and calcium retention capacity were all blocked in the HIF-1+/− mice, thus suggesting a central role of
HIF-1 signalling in IH-mediated cardiovascular disease.
DÉTRAIT et al. [2] explored the role of 12 weeks of IH in the development of ischaemic cardiomyopathy
following left coronary artery ligation in rats. They showed that IH leads to cardiac hypertrophy, cardiac
fibrosis and impaired cardiac function. In parallel, they showed marked sympathetic activation with IH
and impaired calcium homeostasis, suggesting their central roles in IH-mediated cardiovascular disease.
TURNBULL et al. [3] explored the effects of IH on leukocyte gene expression from OSA patients undergoing
continuous positive airway pressure (CPAP) withdrawal with and without supplemental oxygen. Patients
previously treated with CPAP were withdrawn onto 14 nights of supplemental oxygen (5 L·min−1) or
sham in a crossover randomised controlled trial (RCT). TURNBULL et al. [3] identified several genes that
were only upregulated with CPAP withdrawal onto sham, suggesting that gene changes in circulating
leukocytes were IH dependent. The authors also showed activation of key inflammatory pathways,
suggesting a role for NF-κB-mediated inflammation in IH-mediated cardiovascular disease in OSA.
Following with the mechanisms linking IH to cardiovascular disease, THIEL et al. [4] explored the impaired
cerebral vascular reactivity in response to 14 nights of CPAP withdrawal compared to continuation of real
CPAP in moderate to severe OSA patients. Although there was a significant increase in blood pressure
upon CPAP withdrawal and a full recurrence of sleep disordered breathing, there was no significant effect
of CPAP withdrawal on cerebral vascular reactivity (CVR) assessed via blood oxygen level-dependent
magnetic resonance imaging (MRI). Daytime CVR did not show any significant reduction after 2 weeks of
CPAP withdrawal, implying that CVR regulation outlasts other pathophysiological effects of OSA in the
short term.
SUAREZ-GIRON et al. [5] demonstrated that aspirin, a cyclo-oxygenase inhibitor, was able to inhibit
IH-induced aortic damage, including intima-media thickness, elastin disorganisation, elastin
fragmentation, length between fragmented fibre endpoints, aortic wall collagen abundance and mucoid
deposition. These results suggest that aspirin should be prospectively evaluated as adjuvant treatment in
patients with OSA. In a second work, ALMENDROS et al. [6] evaluated the specific role of IH and sleep
fragmentation in the progression of Alzheimer’s disease. The authors found that sleep fragmentation
increases amyloid-β deposition in the hippocampus of a mouse model of Alzheimer’s disease, when
compared to sleep control animals. However, IH had no significant effect on amyloid plaque deposition,
either in the cortex or in the hippocampus.
TRZEPIZUR et al. [7] explored the potential link between OSA and liver injury. Liver stiffness was assessed
using the FibroScan (Echosens, Paris, France), as this is a robust and noninvasive physical marker of liver
fibrosis. They showed that severe OSA (apnoea–hypopnoea index (AHI) >30 events per h) was present in
71.9% of patients with a high liver stiffness measurement (LSM). After adjustment for age, sex, metabolic
syndrome and HOMA-IR index (homeostatic model assessment, insulin resistance), severe OSA remained
highly and independently associated with significantly high LSM, leading to the assumption that this
might predispose OSA patients to a higher risk of liver fibrosis.
REVOL et al. [8] analysed, in VigiBase, the reported cases of sleep apnoea syndrome (SAS) among ticagrelor
users compared to other antiplatelet agents. The reporting odds ratios for ticagrelor were significant for
SAS and for dyspnoea but not for the other antiplatelet agents employed in the study (clopidogrel,
prasugrel and aspirin). REVOL et al. [8] suggested that ticagrelor can induce respiratory drive deregulations
that might explain the occurrence of dyspnoea and SAS.
Epidemiology, phenotypes and cardiometabolic comorbidities of OSA
In Europe, the prevalence of OSA is still unclear. MALHOTRA et al. [9] developed an algorithm of AHI
conversion to estimate the prevalence of OSA for each European country using the most recent
scoring criteria. From 39 European countries, a prevalence of 44.0% was found for AHI ⩾5 events per h
and of 22.7% for AHI ⩾15 events per h. Globally, this leads to a prevalence of 936 million and 424
million people, respectively. These impressive numbers raise a need to increase awareness of OSA, and
https://doi.org/10.1183/23120541.00201-2018 2
SLEEP AND CLINICAL PHYSIOLOGY | I. ALMENDROS ET AL.
to develop new diagnostic and therapeutic approaches that may consider the different phenotypes
of OSA.
In the era of precision medicine, it is important to discuss the limitations of AHI in the assessment of the
diverse spectrum of OSA. To characterise the heterogeneity of OSA into well-defined phenotypes may
improve OSA prognosis and lead to personalised treatments [10]. However, this is a challenging task since
there is still no consensus of how it should be accomplished. Of note, recent cross-sectional studies have
shown the existence of three symptom-based cluster designations of OSA (disturbed sleep, minimally
symptomatic and excessively sleepy) in different samples [11–14]. Using data from the European Sleep
Apnoea Database (ESADA) (n=17325 adult patients, 29.9% women), ANTTALAINEN et al. [15] assessed four
OSA phenotypes based on the presence and absence of excessive daytime sleepiness (EDS) and/or
insomnia symptoms. The phenotype with insomnia alone was the most common in the total sample,
especially in women. However, the association with comorbidities differed among phenotypes. OSA
patients with insomnia alone had a higher prevalence of cardiovascular disease, and those with both
insomnia and EDS showed higher prevalence of metabolic, pulmonary and psychiatric outcomes.
Increased nadir oxygen saturation was an independent protective factor only in the OSA phenotypes that
presented insomnia, corroborating previous literature [16], which suggests that the improvement of
insomnia symptoms may reduce nocturnal hypoxaemia.
In coronary artery disease (CAD) patients, OSA is much more prevalent but the role of its phenotypes is
still unknown, although relevant for disease management. Thus, PEKER et al. [17] presented a secondary
analysis of the RICCADSA trial (Randomized Intervention with CPAP in Coronary Artery Disease and
Sleep Apnoea), comparing the sleepy and nonsleepy OSA phenotypes. The results showed that the
presence of sleepiness (Epworth Sleepiness Scale (ESS) score ⩾10) in OSA patients with CAD was
associated with increased total sleep time and oxygen desaturation index (besides the same level of AHI)
but lower levels of NT-proBNP, which was negatively correlated with slow-wave sleep, ESS score and total
sleep time. In another subset analysis of this cohort, the BALCAN et al. [18] focused on the effects of CPAP
treatment on depressive symptoms using the same rationale of sleepy and nonsleepy OSA phenotypes. At
baseline, depressive symptoms were associated with higher ESS scores. However, CPAP treatment was
effective in improving depressive mood in both sleepy and nonsleepy OSA phenotypes after 3 months. The
improvement remained significant at the 12-month follow-up, being predicted by CPAP adherence, sex,
body mass index (BMI) and reduction of subjective sleepiness.
Although there is a consensus that the treatment of OSA leads to a small decrease in blood pressure [19],
prospective epidemiological evidence is scarce and divergent, with some positive [20, 21] and negative [22, 23]
results from community samples. Thus, HIROTSU et al. [24] assessed the sleep determinants of incident
hypertension in an unselected general population sample of the HypnoLaus cohort, which was followed up
over 5 years. In 1141 individuals free of hypertension at baseline, the authors found that less consolidated
sleep, with lower δ and σ power in non-REM sleep, as well as a worse vascular reactivity characterised by
longer pulse wave amplitude (PWA) drops and less PWA frequency during sleep, were independently
associated with a higher risk of developing hypertension. Although in unadjusted analyses, mild and
moderate to severe OSA as well as hypoxia-related sleep features were associated with incident
hypertension, these results were no longer significant after adjustment for BMI.
However, results from the ESADA cohort showed that mild OSA patients (n=2457) had increased odds
ratio for the prevalence of hypertension compared to non-OSA snorers (n=2517) [25]. Besides the
difference in the study design (cross-sectional versus prospective) and population (clinical versus general),
the definition of hypertension also differed between the two studies. In ESADA, it was based on self-report
of hypertension and/or use of antihypertensive medication, while in HypnoLaus cohort, the standard
average of the two last measurements of systolic and diastolic pressure ⩾140/90 mmHg combined with the
use of antihypertensive medication was used.
Finally, the last presentation of this session answered the unsolved question of the relationship between
OSA and metabolic syndrome (MetS). Using two prospective general population samples (Episono from
Brazil and HypnoLaus from Switzerland), HIROTSU et al. [26] showed for the first time, in a merged
population of 1853 individuals free of MetS at baseline, that moderate to severe OSA was independently
associated with a doubled risk of developing MetS. Using mediation regression analysis, the authors
demonstrated that OSA increased the number of MetS risk factors through mediation of nocturnal
hypoxia, leading to increased waist circumference and glucose levels. However, when assessing the reverse
relationship in a subset analysis of Episono cohort, the presence of MetS was not associated with the
development of new cases of OSA after control for BMI. This new evidence is a proof of concept of
the causal relationship between OSA and MetS, and thus RCTs will be necessary to conclude whether the
treatment of OSA will reduce the incidence of MetS.
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State of the art session: sleep and breathing disorders
Clinical dyspnoea: brain mechanisms and their clinical impact on brain functions
Treating breathlessness via the brain
Dyspnoea is the main symptom in prevalent chronic diseases. This symptom debilitates millions of people
with chronic illness; it is all consuming and life changing. The perception of dyspnoea has a strong
influence on health behaviour and the course of disease. The presence of dyspnoea impacts the brain not
just as an emotional and behavioural factor, but also acting on cognition, changing the way brain works.
Previous studies have shown that dyspnoea is associated with various types of brain activation and
deactivation. In healthy individuals, there is no activation of the premotor cortex during quiet breathing
[27, 28]. However, in amyotrophic lateral sclerosis patients with severe respiratory muscle weakness, an
activation premotor cortex respiratory-related cortical activity was observed [29], while during noninvasive
ventilation (NIV), this activity was attenuated [30], suggesting that this activation appears in the presence
of a mechanical inspiratory load. The activation of the brain does not appear only when dyspnoea is
presented, but also when anticipating the problem. The anticipation of this aversive symptom induces fear
in many patients, resulting in negative and unhealthy behaviours leading to an increasingly sedentary
lifestyle. A study carried out in healthy individuals that provoked dyspnoea by using resistive-load
breathing during functional MRI showed that dyspnoea anticipation activated some brain areas involved in
dyspnoea perception [31].
Additionally, a recent study showed that observing dyspnoea in others causes dyspnoea and increases
brain responses in the absence of respiratory changes, suggesting the negative effect that dyspnoea might
have on the family and caregivers of dyspnoeic patients [32]. Notably, the perception of breathlessness is
not related to objective lung function in chronic respiratory diseases such as chronic obstructive
pulmonary disease (COPD) [33].
Various approaches to relieving dyspnoea without affecting lung function have been described. In a study
that analysed the effect of rehabilitation in dyspnoea perception and the changes produced in the brain in
COPD patients, it was shown that pulmonary rehabilitation was associated with altered neural responses,
which could influence breathlessness perception [34]. Rehabilitation in these patients improved both
dyspnoea and psychological symptoms such as anxiety. Psychological symptoms, such as anxiety and
depression, are very common in COPD and are related to various negative health outcomes, including
dyspnoea. COPD patients with high anxiety levels report more dyspnoea at rest, during exercise and
during pulmonary rehabilitation. Acting on anxiety level using mindfulness therapy has been proposed to
improve dyspnoea perception in COPD patients [35].
Hypoxia, arousals and breathing effort: a roadmap to comorbidities?
OSA and cognition
As previously stated, the relationship between OSA and cardiovascular and metabolic disease has been well
established [5, 36–38]. However, in recent years, evidence linking OSA with other comorbidities, such as
degenerative neurological disease and associated cognitive impairment, has emerged [39]. During the ERS
Congress in Paris, Drs Rosenzweig and Ryan reviewed this emerging field, and explained the mechanism
implicated in this associations. The cognitive domains that can be affected in OSA patients are psychomotor
speed, attention, memory, executive function (higher order cognitive skills such as planning, problem
solving and mental flexibility) and social cognition. ∼80% of OSA patients complain about excessive
daytime sleepiness and cognitive impairments, and 50% of patients report personality changes [40].
Additionally, an association has been described between major depressive disorder, anxiety and
post-traumatic stress disorder. In addition, difficulty in interpersonal relationships, irritability, decreased
work and school efficiency, and car accidents have all been documented in OSA patients. More recently,
the results of a meta-analysis suggest that patients with Alzheimer’s disease may have five times higher
risk of presenting OSA, compared to individuals of similar age without cognitive impairment [41].
Furthermore, it has been reported that individuals with OSA may develop mild cognitive impairment and
Alzheimer’s disease at a younger age [42], and OSA treatment with CPAP delays the age of onset of mild
cognitive impairment.
Exercise is medicine: testing and treating patients with some effort
Exercise intolerance is common in COPD [43]; however, the underlying pathophysiology is multifactorial
and varies between patients [44]. In COPD Global Initiative for Chronic Obstructive Lung Disease
(GOLD) stage 2–4, improvement in endurance with NIV, compared to pursed-lip breathing, during an
interval cycle exercise was achieved. This was associated with reduced dynamic hyperinflation, perceived
dyspnoea and leg discomfort [45]. Improved exercise capacity in COPD patients might have also a
beneficial effect on the increased risk of falling in COPD [46]. REYNAUD et al. [47] proposed a novel cut-off
value of the Timed Up and Go (TUG) test of 11 s to detect fallers in otherwise stable COPD patients.
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In comparison to this value, 13.5 s is proposed in elderly patients >65 years of age [48] and according to a
recent meta-analysis, in contrast to the good sensitivity and specificity in COPD patients, the predictive
value is poor in the healthy elderly [49]. In COPD patients, predictors for worse TUG performance were
COPD severity, low quadriceps strength or a decreased 6-min walk distance (6MWD).
Most people living with asthma can experience exercise-induced bronchoconstriction (EIB). However, EIB
is not exclusively present in people with asthma and a prevalence of 20% has been estimated in the
absence of asthma [50]. According to the American Thoracic Society guidelines released in 2013 and the
later update in 2016, symptoms suggestive of EIB require further evaluation through exercise challenge or
other indirect bronchial provocation tests [51, 52]. A ⩾10% fall in forced expiratory volume in 1 s (FEV1)
after an exercise challenge is used for diagnosis. Pharmacological treatments of EIB include symptom
prevention, such as inhalation of short-acting β2-agonists or anticholinergic agents. The presence of
different endotypes has been suggested to be responsible for the high variability in individual responses
to bronchodilators prescribed to prevent EIB. Two distinct inflammatory endotypes have been describe:
the T2-high endotype, characterised by eosinophilic inflammation; and the T2-low endotype,
characterised by neutrophilic inflammation. BONINI et al. [53] found that T2-endotype influences
bronchodilator response in EIB. Specifically, they found no protective effect on EIB in the T2-high group
from inhalation of the anticholinergic ipratropium compared to inhalation of the β2-agonist salbutamol.
To investigate whether the forced oscillation technique (FOT) [54] could produce equivalent measures of
airway calibre post-exercise challenge to maximal expiratory manoeuvres, SECCOMBE et al. [55] compared
both techniques to identify patients with EIB independent of bronchial hyperresponsiveness (BHR) in
asthma patients with and without BHR versus controls. The FOT parameters resistance and reactance at
5 Hz oscillation frequency correlated well with post-exercise FEV1 manoeuvres, and might serve as a tool
to distinguish asthmatic patients with EIB from those with BHR and as an alternative to post-exercise
FEV1 manoeuvres.
In contrast to EIB, breathing complaints during exercise that relieve within a few minutes after exercise
termination are characteristic for exercise-induced inspiratory symptoms, i.e. exercise-induced laryngeal
obstruction (EILO). Continuous laryngoscopy exercise (CLE) testing is the gold standard for diagnosing
EILO. However, this intervention could influence the maximum gas exchange values achieved. HAMMER
et al. [56] reported no differences in exercise performance between maximal treadmill cardiopulmonary
exercise testing (CPET) with and without CLE in regard to maximal oxygen uptake in healthy athletes. A
novel approach to EILO was introduced during the ERS Congress: a proof of concept study using laser
surgery reducing supraglottic obstruction. This resulted in better post-surgery exercise performance and
lower perceived dyspnoea in two subjects with severe EILO compared to pre-surgery symptom-limited
CPET [57].
Another study in patients with excessive dynamic airway collapse showed improved 6-min walk
performance when applying CPAP compared to subtherapeutic CPAP therapy [58]. In contrast to
short-term improvements, EDVARSEN et al. [59] investigated whether 20 weeks of high-intensity training
after surgery has an effect on 5-year survival in patients with lung cancer. Although no differences were
reported in the 5-year survival, they found that the training group lived, on average, several months longer
than the control group.
Respiratory muscles at rest, during exercise and in the critically ill patient
Beyond lung function, respiratory muscle dysfunction (RMD) is currently considered a major comorbidity in
COPD. In fact, RMD can modulate prognosis, exercise tolerance and quality of life in COPD patients [60].
In COPD, even though respiratory muscles may show some positive adaptations induced by the increased
respiratory overload [60, 61], they also have reduced endurance [62, 63] and strength, presenting only 59%
of inspiratory and 69% expiratory muscle strength compared with control values [64]. This goes beyond
the level of impairment observed in skeletal muscle in those patients (75% of control values for lower limb
and 78% for upper limbs) [64]. Frequent exacerbations [65] negatively impact muscle mass and function
in these patients. Thus, the cross-sectional area of intercostal muscles was significantly reduced by 14% in
fragile COPD patients compared to controls [66]. Moreover, hypoxia and oxidative stress seem to play a
determinant role [67] in the phenotypic and functional muscle modifications [63], which are probably
underpinned by epigenetic modifications [68, 69].
The exercise limitation caused by RMD [70] and the increased work of breathing as a result of dynamic
hyperinflation [71] contribute to the uncomfortable feeling of breathlessness [72]. Rather than a pure
structural muscle impairment, RMD must be considered as a neuromuscular dysfunction [72]. In terms of
the diaphragm, in COPD patients, the increased work of breathing and the reduced muscle capacity can
lead to an increased neural respiratory drive (NRD) even at rest [73]. Thus, NRD at rest was significantly
increased in COPD patients compared to healthy subjects [74]. During exercise, NRD in moderate to
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severe COPD patients is characterised by neuroventilatory uncoupling [75] and is associated with
breathlessness intensity [76]. Interestingly, diaphragm electromyogram expressed as a percentage of
maximum is also a strong predictor of dyspnoea in fibrotic interstitial lung disease [77]. Thus, it has been
proposed as a useful physiological biomarker for breathlessness in COPD [76] and in fibrotic interstitial
lung disease [77].
It has been reported that 64% of patients within 24 h following their admission to the intensive care unit
(ICU) can develop diaphragm dysfunction [78]. In addition, a more recent prospective longitudinal study
has reported that this percentage can be increased up to 79% in critically ill patients receiving prolonged
mechanical ventilation at some point during their ICU stay [79]. Diaphragm dysfunction can be developed
as a consequence of multiorgan failure, critical illness polyneuropathy and/or myopathy, hypercatabolism
or prolonged mechanical ventilation [80]. The association of diaphragm dysfunction with a poorer
prognosis [78], a higher rate of mechanical ventilation weaning failure and an increased duration of
mechanical ventilator [79], has increased its interest in intensive care.
Diaphragm weakness can be assessed by measuring the thickening fraction of the diaphragm by
ultrasonography [81] and has recently shown similarly strong performance to twitch tracheal pressure in
response to magnetic phrenic stimulation in the prediction of failure of the spontaneous breathing trial [82].
In severe acute exacerbation of COPD, ultrasonography assessment of diaphragm dysfunction is a reliable
and accurate tool to identify patients at major risk of NIV failure and worse prognosis [83].
Inspiratory muscle training (IMT) is of great interest to prevent RMD. In COPD, it has been suggested
that IMT must be combined with general exercise training (GET), which increases ventilatory pump
capacity and provides a reduction in ventilatory requirements. Two recent RCTs assessed the effects of
3 [84] or 4 weeks [85] of IMT combined with GET, in comparison to sham IMT combined with GET [84],
or GET alone [85]. Both failed to show any improvement in 6MWD or health-related quality of life
outcomes, despite improvements in maximal inspiratory pressure [84]. A 12-week RCT conducted in
COPD patients with inspiratory muscle weakness assessed the effects of IMT versus sham IMT both
combined with GET on inspiratory muscle function, exercise capacity and health-related quality of life [86].
In contrast to 6MWD, some improvements were observed in patients with marked inspiratory muscle
weakness on the endurance cycling test. In acute conditions, particularly in the ICU, IMT has been shown
to be an adjunct to the treatment of patients with mechanical ventilation weaning difficulty [87]. Further
research is still ongoing, including a RCT (www.clinicaltrials.gov identifier number NCT03240263) to
evaluate the effects of a novel IMT method on weaning outcomes in selected patients with weaning
difficulties [88].
Mechanisms that underlie exercise limitation in various respiratory diseases
The increase in sympathetic vasoconstrictor outflow to the limb muscles upon activation of a metaboreflex
triggered by respiratory muscle fatigue has been proposed as one potential mechanism limiting
whole-body exercise capacity in COPD patients [89]. JOHNSON et al. [90] investigated whether this
mechanism may limit single-leg knee extensor exercise tolerance. They showed that following maximal
volitional hyperpnea, single-leg knee extensor exercise tolerance was lower compared to exercise conditions
without imposing respiratory muscle fatigue. Nevertheless, the decrease in exercise tolerance was not
associated with greater leg muscle fatigue after exercise. Authors concluded that the reduction in single-leg
exercise tolerance because of prior fatigue of the respiratory muscle was not via acceleration of peripheral
muscle fatigue secondary to activation of respiratory muscle metaboreflex, but due to perceptual responses,
as patients demonstrated greater perception of effort. Evidently, these results open new perspectives and
challenges.
Regarding pulmonary arterial hypertension (PAH), DORNELES et al. [91] investigated whether ventilatory
constrains contribute to intolerable dyspnoea sensations during exercise in these patients. They
demonstrated that for a given rate of work during cycling, patients with PAH presented abnormal lung
mechanics compared to healthy controls, manifested by higher minute ventilation, tachypnoea, decrease in
inspiratory capacity and restriction of inspiratory reserve volume. They also highlighted the need for future
studies aiming at investigating the effects of pharmacological and nonpharmacological interventions on
lessening inspiratory constraints and, thus, dyspnoea sensations in this population.
With respect to OSA, MARILLIER et al. [92] investigated the cerebrovascular haemodynamic and
oxygenation responses during exercise and in response to 8 weeks of CPAP. The study revealed that
patients with OSA exhibited an insufficient increase in cerebral haemodynamic responses during exercise
to the limit of tolerance that were associated with lower increases in total haemoglobin concentration. The
study advanced our previous knowledge by demonstrating that restrictions in cerebral perfusion might
contribute to exercise intolerance in OSA patients. The study also demonstrated that both exercise capacity
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and cerebral oxygenation remained unaffected after 8 weeks of CPAP treatment, thus indicating the need
for future research in this field.
FREGONEZI et al. [93] carried out a study to ascertain whether chest wall and compartmental volume
responses differ between mild asthmatic patients and healthy subjects. The study demonstrated that during
mild exercise, asthma patients adopted a different breathing pattern to healthy individuals that was
characterised by rapid shallow breathing, existence of end-expiratory chest wall dynamic hyperinflation,
and thoraco-abdominal asynchrony between the rib cage and abdominal chest compartments. The
investigators concluded that these alternations in breathing pattern may contribute to exercise limitation in
mild asthmatic patients.
Regarding cystic fibrosis (CF), DI PAOLO et al. [94] highlighted the importance of assessing ventilatory
efficiency (V′E/V′CO2) during incremental CPET. They performed a multicentre observational study
comparing the slopes and intercepts of the V′E/V′CO2 relationship, and the lowest value between CF
patients with normal to moderate impairment in lung function and age/sex-matched healthy subjects.
Ventilatory inefficiency was shown by higher values of V′E/V′CO2 slope and nadir in CF compared to
healthy individuals. This finding represented a clear feature of CF patients even among those with normal
lung function. Accordingly, these indices may represent valuable outcomes for prospective trials, and for
evaluating the effectiveness of different pharmacological and nonpharmacological treatments in CF.
BAR-YOSEPH et al. [95] compared exercise capacity in mild CF, non-CF bronchiectasis and healthy controls.
Although the study demonstrated that peak exercise capacity during CPET was comparable between both
groups of patients and age-matched healthy controls, both mild CF and non-CF bronchiectasis patients
had breathing limitations that were confirmed by low breathing reserves at the end of exercise. This should
be acknowledged as a potential limitation in exercise capacity in these patients.
Finally, DOURADO et al. [96] presented the findings from the cross sectional EPIMOV study, which was
conducted on 1368 adults aged between 18 and 80 years old. The aim of this study was to determine, by
measuring the peak oxygen uptake during CPET, the role of physical activity and cardiorespiratory fitness
in the relationship between lung function with arterial hypertension [97]. This study identified only peak
oxygen uptake variables as significant mediators for the relationships between lung function parameters
and hypertension (Sobel–Goodman test results ranged between 60% and 79%). The authors concluded
that low cardiorespiratory fitness may provide the pathway for understanding the role of lung function as
predictor of incident arterial hypertension from young adults to the elderly population.
Advances in exercise pathophysiology
This session provided new insights and interesting physiological discussions on topics that comprise the
routine management of patients with COPD. All studies emphasised the importance of assessing responses
to exercise in order to tackle several clinical challenges we are faced with when caring for COPD patients.
The study presented by BERTON et al. [98] sought to determine whether dual bronchodilator treatment
improved exercise haemodynamics because of reduced static and dynamic hyperinflation in patients with
COPD. Signal morphology impedance cardiography was used to assess cardiac output and blood flow to
the quadriceps. In a double-blind crossover study in which 20 patients exercised at 75% of peak work rate
after a single dose of olandaterol+tiotropium or placebo, the authors found that dual bronchodilation
increased resting and peak inspiratory capacity, reduced isotime dyspnoea and improved exercise
endurance, but no differences were seen either in central or peripheral haemodynamics.
The second presentation, by HAJIAN et al. [99] examined the impact of pulsed inhaled nitric oxide (iNO)
on pulmonary hypertension and exercise tolerance in hypoxic COPD patients. The rationale behind this
proof of concept study was that iNO would be able to cause vasodilation and reduce pulmonary artery
pressures without worsening ventilation/perfusion mismatch, given that iNO would diffuse predominantly
to areas of higher alveolar volume. After 4 weeks of pulsed iNO, patients showed a reduction in systolic
pulmonary artery pressure and significantly increased 6MWD without worsening gas exchange. In fact,
functional respiratory imaging analysis demonstrated that there was a significant association between
regional ventilation and regional vasodilation during iNO therapy. While it could be argued that the lack
of a familiarisation 6MWD might have overestimated the clinical response to iNO, the physiological
rationale was confirmed and the results are in line with that of recent studies investigating the effects of
inhaled iloprost in COPD [100].
The study presented by SOUZA et al. [101] showed that NIV increases inspiratory capacity and reduces
isotime dyspnoea in patients with overlapping COPD–heart failure (HF) but not in HF subjects without
COPD. In addition, the use of bilevel ventilation led to longer endurance time at high-intensity exercise
testing in COPD-HF subjects compared to sham ventilation, although this finding was difficult to interpret
given the authors’ choice of exercise protocol and the small sample size. Nevertheless, the results
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concerning improvement in symptoms and ventilatory mechanics seemed consistent and provided
physiological rationale for the use of NIV in COPD-HF patients during exercise in a rehabilitation
programme.
FURIAN et al. [102] presented a study showing that the acute use of dexamethasone can attenuate the
increase in cerebral blood flow in response to high altitude and blunts systemic arterial pressure increase
during isometric exercise compared to placebo, thus potentially preventing cerebral hyperperfusion
without leading to tissue hypoxia in GOLD I–II COPD patients. In turn, BEDIN et al. [103] suggested that
a peak oxygen consumption <15 mL·kg−1·min−1 predicts the occurrence of postoperative cardiopulmonary
complications in patients undergoing lung resection surgery, regardless of the presence of comorbid
COPD. Finally, PAPAPOSTOLOU et al. [104] retrospectively analysed demographics, pulmonary function and
exercise data of 800 COPD subjects to develop an equation that could predict peak work rate on
incremental cycle ergometry. They revealed that FEV1 and diffusing capacity of the lung for carbon
monoxide were the variables most strongly associated with peak work rate. When tested prospectively in a
small sample of 15 GOLD II–III COPD patients, there was a good correlation between actual and
predicted peak work rate but the accuracy of these estimated values was somewhat variable.
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